Cargando…

Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery

SIMPLE SUMMARY: Nano-drug delivery systems serve as Trojan horses to carry therapeutic drugs as cargos and deliver them to target cells. The specificity of these delivery vehicles to a particular cell type can be improved if the surface of the vehicles is chemically modified in such a manner that th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kou, Longfa, Yao, Qing, Zhang, Hailin, Chu, Maoping, Bhutia, Yangzom D., Chen, Ruijie, Ganapathy, Vadivel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599460/
https://www.ncbi.nlm.nih.gov/pubmed/33019627
http://dx.doi.org/10.3390/cancers12102837
_version_ 1783602879881281536
author Kou, Longfa
Yao, Qing
Zhang, Hailin
Chu, Maoping
Bhutia, Yangzom D.
Chen, Ruijie
Ganapathy, Vadivel
author_facet Kou, Longfa
Yao, Qing
Zhang, Hailin
Chu, Maoping
Bhutia, Yangzom D.
Chen, Ruijie
Ganapathy, Vadivel
author_sort Kou, Longfa
collection PubMed
description SIMPLE SUMMARY: Nano-drug delivery systems serve as Trojan horses to carry therapeutic drugs as cargos and deliver them to target cells. The specificity of these delivery vehicles to a particular cell type can be improved if the surface of the vehicles is chemically modified in such a manner that they are recognized and attracted to the target cell. This can be accomplished if the target cell selectively expresses a receptor or transporter and the surface of the drug-delivery vehicles is conjugated with the receptor agonist or the transporter substrate. In this review, we detail published literature on the successful exploitation of plasma membrane transporters for this purpose. In particular, this review emphasizes the delivery of chemotherapeutic drugs to cancer cells by targeting the nano-delivery systems specifically to certain transporters that are selectively upregulated in cancer cells. ABSTRACT: Nano-devices are recognized as increasingly attractive to deliver therapeutics to target cells. The specificity of this approach can be improved by modifying the surface of the delivery vehicles such that they are recognized by the target cells. In the past, cell-surface receptors were exploited for this purpose, but plasma membrane transporters also hold similar potential. Selective transporters are often highly expressed in biological barriers (e.g., intestinal barrier, blood–brain barrier, and blood–retinal barrier) in a site-specific manner, and play a key role in the vectorial transfer of nutrients. Similarly, selective transporters are also overexpressed in the plasma membrane of specific cell types under pathological states to meet the biological needs demanded by such conditions. Nano-drug delivery systems could be strategically modified to make them recognizable by these transporters to enhance the transfer of drugs across the biological barriers or to selectively expose specific cell types to therapeutic drugs. Here, we provide a comprehensive review and detailed evaluation of the recent advances in the field of transporter-targeted nano-drug delivery systems. We specifically focus on areas related to intestinal absorption, transfer across blood–brain barrier, tumor-cell selective targeting, ocular drug delivery, identification of the transporters appropriate for this purpose, and details of the rationale for the approach.
format Online
Article
Text
id pubmed-7599460
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75994602020-11-01 Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery Kou, Longfa Yao, Qing Zhang, Hailin Chu, Maoping Bhutia, Yangzom D. Chen, Ruijie Ganapathy, Vadivel Cancers (Basel) Review SIMPLE SUMMARY: Nano-drug delivery systems serve as Trojan horses to carry therapeutic drugs as cargos and deliver them to target cells. The specificity of these delivery vehicles to a particular cell type can be improved if the surface of the vehicles is chemically modified in such a manner that they are recognized and attracted to the target cell. This can be accomplished if the target cell selectively expresses a receptor or transporter and the surface of the drug-delivery vehicles is conjugated with the receptor agonist or the transporter substrate. In this review, we detail published literature on the successful exploitation of plasma membrane transporters for this purpose. In particular, this review emphasizes the delivery of chemotherapeutic drugs to cancer cells by targeting the nano-delivery systems specifically to certain transporters that are selectively upregulated in cancer cells. ABSTRACT: Nano-devices are recognized as increasingly attractive to deliver therapeutics to target cells. The specificity of this approach can be improved by modifying the surface of the delivery vehicles such that they are recognized by the target cells. In the past, cell-surface receptors were exploited for this purpose, but plasma membrane transporters also hold similar potential. Selective transporters are often highly expressed in biological barriers (e.g., intestinal barrier, blood–brain barrier, and blood–retinal barrier) in a site-specific manner, and play a key role in the vectorial transfer of nutrients. Similarly, selective transporters are also overexpressed in the plasma membrane of specific cell types under pathological states to meet the biological needs demanded by such conditions. Nano-drug delivery systems could be strategically modified to make them recognizable by these transporters to enhance the transfer of drugs across the biological barriers or to selectively expose specific cell types to therapeutic drugs. Here, we provide a comprehensive review and detailed evaluation of the recent advances in the field of transporter-targeted nano-drug delivery systems. We specifically focus on areas related to intestinal absorption, transfer across blood–brain barrier, tumor-cell selective targeting, ocular drug delivery, identification of the transporters appropriate for this purpose, and details of the rationale for the approach. MDPI 2020-10-01 /pmc/articles/PMC7599460/ /pubmed/33019627 http://dx.doi.org/10.3390/cancers12102837 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kou, Longfa
Yao, Qing
Zhang, Hailin
Chu, Maoping
Bhutia, Yangzom D.
Chen, Ruijie
Ganapathy, Vadivel
Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery
title Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery
title_full Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery
title_fullStr Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery
title_full_unstemmed Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery
title_short Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery
title_sort transporter-targeted nano-sized vehicles for enhanced and site-specific drug delivery
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599460/
https://www.ncbi.nlm.nih.gov/pubmed/33019627
http://dx.doi.org/10.3390/cancers12102837
work_keys_str_mv AT koulongfa transportertargetednanosizedvehiclesforenhancedandsitespecificdrugdelivery
AT yaoqing transportertargetednanosizedvehiclesforenhancedandsitespecificdrugdelivery
AT zhanghailin transportertargetednanosizedvehiclesforenhancedandsitespecificdrugdelivery
AT chumaoping transportertargetednanosizedvehiclesforenhancedandsitespecificdrugdelivery
AT bhutiayangzomd transportertargetednanosizedvehiclesforenhancedandsitespecificdrugdelivery
AT chenruijie transportertargetednanosizedvehiclesforenhancedandsitespecificdrugdelivery
AT ganapathyvadivel transportertargetednanosizedvehiclesforenhancedandsitespecificdrugdelivery